Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.93
MSLI's Cash to Debt is ranked higher than
64% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. MSLI: 1.93 )
MSLI' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 1.93

Equity to Asset 0.72
MSLI's Equity to Asset is ranked higher than
77% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. MSLI: 0.72 )
MSLI' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.94
Current: 0.72

0.18
0.94
Interest Coverage 1.01
MSLI's Interest Coverage is ranked lower than
53% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MSLI: 1.01 )
MSLI' s 10-Year Interest Coverage Range
Min: 1.01   Max: 9999.99
Current: 1.01

1.01
9999.99
F-Score: 5
Z-Score: 2.82
M-Score: -3.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 6.28
MSLI's Operating margin (%) is ranked higher than
82% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. MSLI: 6.28 )
MSLI' s 10-Year Operating margin (%) Range
Min: -1112.12   Max: 19.4
Current: 6.28

-1112.12
19.4
Net-margin (%) -12.18
MSLI's Net-margin (%) is ranked higher than
78% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. MSLI: -12.18 )
MSLI' s 10-Year Net-margin (%) Range
Min: -1787.71   Max: 30.37
Current: -12.18

-1787.71
30.37
ROE (%) -3.73
MSLI's ROE (%) is ranked higher than
80% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. MSLI: -3.73 )
MSLI' s 10-Year ROE (%) Range
Min: -545.85   Max: 30.77
Current: -3.73

-545.85
30.77
ROA (%) -2.70
MSLI's ROA (%) is ranked higher than
81% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. MSLI: -2.70 )
MSLI' s 10-Year ROA (%) Range
Min: -108.55   Max: 13.79
Current: -2.7

-108.55
13.79
ROC (Joel Greenblatt) (%) 103.84
MSLI's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. MSLI: 103.84 )
MSLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -601.2   Max: 154.69
Current: 103.84

-601.2
154.69
Revenue Growth (%) 83.10
MSLI's Revenue Growth (%) is ranked higher than
70% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. MSLI: 83.10 )
MSLI' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 86.8
Current: 83.1

-100
86.8
EPS Growth (%) -54.20
MSLI's EPS Growth (%) is ranked higher than
55% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. MSLI: -54.20 )
MSLI' s 10-Year EPS Growth (%) Range
Min: -54.2   Max: 108
Current: -54.2

-54.2
108
» MSLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MSLI Guru Trades in Q3 2013

Jim Simons 304,100 sh (+3.05%)
» More
Q4 2013

MSLI Guru Trades in Q4 2013

Jim Simons 341,200 sh (+12.2%)
» More
Q1 2014

MSLI Guru Trades in Q1 2014

Jim Simons 385,300 sh (+12.92%)
» More
Q2 2014

MSLI Guru Trades in Q2 2014

Jim Simons 587,900 sh (+52.58%)
» More
» Details

Insider Trades

Latest Guru Trades with MSLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.10
MSLI's P/B is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. MSLI: 1.10 )
MSLI' s 10-Year P/B Range
Min: 0.29   Max: 3.64
Current: 1.1

0.29
3.64
P/S 2.90
MSLI's P/S is ranked higher than
90% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. MSLI: 2.90 )
MSLI' s 10-Year P/S Range
Min: 0.71   Max: 31.31
Current: 2.9

0.71
31.31
PFCF 7.00
MSLI's PFCF is ranked higher than
99% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MSLI: 7.00 )
MSLI' s 10-Year PFCF Range
Min: 1.3   Max: 175
Current: 7

1.3
175
EV-to-EBIT 74.39
MSLI's EV-to-EBIT is ranked higher than
85% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MSLI: 74.39 )
MSLI' s 10-Year EV-to-EBIT Range
Min: 0.6   Max: 68.2
Current: 74.39

0.6
68.2
Current Ratio 5.56
MSLI's Current Ratio is ranked higher than
79% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. MSLI: 5.56 )
MSLI' s 10-Year Current Ratio Range
Min: 0.24   Max: 14.42
Current: 5.56

0.24
14.42
Quick Ratio 5.31
MSLI's Quick Ratio is ranked higher than
80% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. MSLI: 5.31 )
MSLI' s 10-Year Quick Ratio Range
Min: 0.19   Max: 14.42
Current: 5.31

0.19
14.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.14
MSLI's Price/Net Cash is ranked higher than
93% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. MSLI: 4.14 )
MSLI' s 10-Year Price/Net Cash Range
Min: 0.49   Max: 40.11
Current: 4.14

0.49
40.11
Price/Net Current Asset Value 3.62
MSLI's Price/Net Current Asset Value is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. MSLI: 3.62 )
MSLI' s 10-Year Price/Net Current Asset Value Range
Min: 0.44   Max: 106.45
Current: 3.62

0.44
106.45
Price/Tangible Book 3.38
MSLI's Price/Tangible Book is ranked higher than
86% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. MSLI: 3.38 )
MSLI' s 10-Year Price/Tangible Book Range
Min: 0.38   Max: 14.86
Current: 3.38

0.38
14.86
Price/DCF (Projected) 1.02
MSLI's Price/DCF (Projected) is ranked higher than
99% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MSLI: 1.02 )
MSLI' s 10-Year Price/DCF (Projected) Range
Min: 0.18   Max: 2.62
Current: 1.02

0.18
2.62
Price/Median PS Value 0.98
MSLI's Price/Median PS Value is ranked higher than
70% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. MSLI: 0.98 )
MSLI' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 7.84
Current: 0.98

0.02
7.84
Earnings Yield (Greenblatt) 1.30
MSLI's Earnings Yield (Greenblatt) is ranked higher than
51% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. MSLI: 1.30 )
MSLI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 158.2
Current: 1.3

1.5
158.2
Forward Rate of Return (Yacktman) 5.83
MSLI's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. MSLI: 5.83 )
MSLI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.6   Max: 20.9
Current: 5.83

-10.6
20.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:MSL.Canada
Merus Labs International Inc is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include: On patent but at maturity stage of product life cycle; Branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory. Competition also comes from generic companies, which develop and commercialize formulations that are identical to marketed brands.
» More Articles for NAS:MSLI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest volume increases Sep 17 2014
Merus Labs International (MSLI) Upgraded From Sell to Hold Sep 16 2014
Merus Labs International Inc. Announces Acquisition of Sintrom(R) Sep 08 2014
Merus Labs International Inc. Announces Completion of $7 Million Financing Transaction With Dacha... Aug 14 2014
Merus Labs International Inc. Announces Third Quarter Results for Fiscal 2014 Aug 12 2014
Merus Labs International Inc. Subsidiary Signs Product Acquisition Letter of Intent Aug 07 2014
3 Stocks Pushing The Drugs Industry Lower Jul 17 2014
Merus Labs International Inc. Announces Conversion of $10 Million Convertible Debentures Jul 17 2014
Merus Labs International Inc. Announces Closing of $10 Million Preferred Share Financing Jul 11 2014
Merus Signs Definitive Acquisition Agreement With Dacha Strategic Metals Inc. Jul 04 2014
Merus Labs International Inc. Announces Closing of $31.3 Million Bought Deal Financing, Including... Jun 19 2014
Merus to Present at Bloom Burton & Co. Healthcare Investor Conference Jun 16 2014
Dacha Strategic Metals: An Exit For Some, An Arbitrage Opportunity For Others Jun 14 2014
Merus Labs International Inc. Announces Increase to Previously Announced Financing Jun 12 2014
Merus Labs International Inc. Announces Increase to Previously Announced Financing Jun 12 2014
Merus Labs International Inc. Announces $22.1 Million Bought Deal Financing Jun 11 2014
Merus Labs International Inc. Announces $22.1 Million Bought Deal Financing Jun 11 2014
Merus Labs International Inc. Announces Aggregate $21 Million Financing Transactions Jun 10 2014
Merus Labs International Inc. Notified of a Canadian ANDS Filing Jun 03 2014
Merus Labs International Inc. Announces Board Appointment May 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK